Opinion|Videos|January 16, 2026
Real-World Outcomes for First-Line Luspatercept in Lower-Risk MDS
Author(s)Amer Zeidan, MBBS, MD
Amer Zeidan, MBBS, details data from ASH 2025 on real-world outcomes with luspatercept in lower-risk MDS.
Advertisement
Episodes in this series
Amer Zeidan, MBBS, reviews real-world data presented at the 2025 ASH Annual Meeting and Exposition evaluating first-line luspatercept (Reblozyl) in patients with lower-risk myelodysplastic syndromes (MDS). He discusses effectiveness outcomes, transfusion independence rates, and how these findings compare with results from clinical trials. Zeidan places these data in context of routine clinical practice and evolving treatment algorithms.
Advertisement
Related to this article
Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.
Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.
Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5